Post-Market Clinical Investigation of the IotaSOFT Insertion System
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cochlear Implantation with Robotic-Assisted Insertion System.
- Who it may be relevant to
- Registry conditions: Hearing Loss, Cochlear, Cochlear Implantation, Hearing Loss, Sensorineural. Basic parameters: from 12 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Post-Market Clinical Investigation of the IotaSOFT Insertion System for Use with Cochlear Implant Surgery
Overview
The purpose of the proposed study is to evaluate the continued safety of the iotaSOFT Insertion System when used by a surgeon to assist with inserting a CI electrode array in one ear per subject
Detailed description
available iotaSOFT Insertion System when used per intended use for insertion of a cochlear implant electrode array in subjects 12 years and older. The purpose of the study is to collect additional safety data in retrospective and prospective subjects. The primary object of the study is to demonstrate post-market safe use of the commercially available iotaSOFT Insertion System. The secondary objective of the study is to define procedural characteristics including device deficiencies, electrode array insertion speed, rate of tip fold-over, and objective measures of cochlear implant functionality to demonstrate effective use of the commercially available iotaSOFT Insertion System.
Interventions
- Device Cochlear Implantation with Robotic-Assisted Insertion System
The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.
Primary outcome measures
- Number of Subjects Experiencing a Serious or Related Adverse Event Due to Use of the iotaSOFT Insertion System During Cochlear Implant Surgery [Time frame: 1 month post-activation]
Secondary outcome measures (1)
- Number of device deficiencies related to the use of the iotaSOFT Insertion System [Time frame: 1 month post-activation]
Eligibility criteria
Inclusion criteria
- Candidates with sensorineural hearing loss who received or will receive unilateral or bilateral cochlear implantation according to indications for use with FDA approved cochlear implant devices, as listed below:
- Advanced Bionics HiFocus SlimJ
- Cochlear Slim Straight
- MED-EL Flex 24 and 28
- Age 12 years or older at the time of CI surgery.
- Willingness to participate in the study and able to comply with the follow-up visit requirements.
Exclusion criteria
- Prior cochlear implantation in the ear to be implanted.
- Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or present an increased risk of aberrant insertion.
- Craniofacial abnormality, temporal squamosal skull thickness less than 3mm, major cochlear lesions (e.g., fibrosis, fracture, or ossification), or cochlear malformations.
- Deafness due to lesions of the acoustic nerve or central auditory pathway.
- Diagnosis of auditory neuropathy.
- Active middle-ear infection or tympanic membrane perforation in the presence of active middle ear disease.
- Absence of cochlear development.
- Additional medical concerns that would prevent participation in evaluations as determined by the investigator.
- Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the procedure and investigational device.
- Non-native English speakers who are unable to read, understand and/or speak English for completion of required procedures
- Planned or current participation in a clinical study of an investigational device or drug.
- Must not fit the definition of a vulnerable subjects, as per FDA regulations 21 CFR Parts 50 and 56
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 3 centers
- Indiana University — Indianapolis
- University of Iowa — Iowa City
- Oregon Health and Sciences University — Portland
Identifiers
NCT: NCT06664697 · ICI2401